The rate and outcomes of reducing re hospitalizations with a treatment regimen including dapagliflozin in heart failure with reduced ejection fraction without diabetes patients

Heart failure, a cardiovascular disease with a substantial disease burden, often leads to frequent hospitalizations for acute episodes. The readmission rate is estimated to be around 30-50%, resulting in high costs for both pharmacological and non-pharmacological treatments. Additionally, heart failure is associated with a considerable mortality rate, ranging from 48-57%.